We believe that preclinical studies can therefore greatly contribute to exploring the potential role of GRPR-targeting applications in the context of the currently applied PSMA targeting for detection and treatment of PCa by studying a broad patient population using the same methodology. The gene discussed is FOLH1; the disease is posterior cortical atrophy.